LipUm focuses on developing a biological anti-inflammatory drug candidate for Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA), aiming to improve the quality of life for millions of patients. The company also explores treatments for other chronic inflammatory conditions like Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Their drug candidate, SOL-116, is a humanized antibody that targets a previously overlooked molecule in the immune system, providing a safer and more effective treatment option with potentially fewer adverse effects than current therapies. LipUm's innovative approach has the potential to revolutionize the treatment of chronic inflammatory diseases.